AI Article Synopsis
- CD19-specific CAR T cell therapy shows promising initial response rates and long-term remissions in some adults with relapsed B-cell acute lymphoblastic leukemia (ALL).
- A clinical trial at MSKCC found that 26% of patients experienced severe cytokine release syndrome post-infusion, but overall, 83% achieved complete remission with a median overall survival of 12.9 months.
- Patients with low disease burden before treatment had significantly better outcomes, with median overall survival reaching 20.1 months and fewer adverse events compared to those with higher disease burden.
Article Abstract
Background: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients.
Methods: We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics.
Results: A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden.
Conclusions: In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637939 | PMC |
| http://dx.doi.org/10.1056/NEJMoa1709919 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
G-quadruplexes (G4s) are four-stranded alternative secondary structures formed by guanine-rich nucleic acids and are prevalent across the human genome. G4s are enzymatically resolved using specialized helicases. Previous studies showed that DEAH-box Helicase 36 (DHX36/G4R1/RHAU), has the highest specificity and affinity for G4 structures.
View Article and Find Full Text PDFReal time-PCR a diagnostic tool for reporting copy number variation and relative gene-expression changes in pediatric B-cell acute lymphoblastic leukemia-a pilot study.
Biol Methods Protoc
December 2024
Division of Molecular Medicine, St John's Research Institute, St John's National Academy of Health Sciences (a Unit of CBCI Society for Medical Education), Bangalore 560034, Karnataka, India.
Real time-polymerase chain reaction (RT-PCR) is used routinely in clinical practice as a cost-effective method for molecular diagnostics. Research in pediatric B-cell Acute Lymphoblastic Leukemia (ped B-ALL) suggests that apart from cytogenetics and clinical features, there is a need to include Copy number variation (CNV) in select genes at diagnosis, for upfront stratification of patients. Using ped B-ALL as a model, we have developed a RT-PCR-based iterative probability scoring method for reporting CNVs, and relative gene-expression changes.
View Article and Find Full Text PDFImpact of obesity on outcome in children diagnosed with cancer in Canada: A report from Cancer in Young People in Canada.
Cancer
January 2025
Division of Pediatric Hematology-Oncology, Department of Pediatrics, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) de Sainte-Justine, Montreal, Quebec, Canada.
Background: Childhood obesity can result in adverse health outcomes. The objectives of this study were to describe the prevalence of obesity and determine the association between obesity at cancer diagnosis and event-free survival (EFS) and overall survival (OS) in children diagnosed with cancer in Canada.
Methods: The authors conducted a retrospective cohort study using the Cancer in Young People in Canada database, including all children with newly diagnosed cancer aged 2-18 years across Canada from 2001 to 2020.
Commentary on "Epigenome-wide analysis across the development span of pediatric acute lymphoblastic leukemia: backtracking to birth".
Mol Cancer
January 2025
Molecular Epidemiology (MOLE), Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
VTRNA2-1 is a polymorphically imprinted locus. The proportion of individuals with a maternally imprinted VTRNA2-1 locus is consistently approximately 75% in populations of European origin, with the remaining circa 25% having a non-methylated VTRNA2-1 locus. Recently, VTRNA2-1 hypermethylation at birth was suggested to be a precursor of paediatric acute lymphoblastic leukaemia with biomarker potential.
View Article and Find Full Text PDFAn efficient deep learning system for automatic detection of Acute Lymphoblastic Leukemia.
ISA Trans
January 2025
Department of Electronics and Telecommunication, C. V. Raman Global University, Bhubaneswar 752054, Odisha, India. Electronic address:
Early and highly accurate detection of rapidly damaging deadly disease like Acute Lymphoblastic Leukemia (ALL) is essential for providing appropriate treatment to save valuable lives. Recent development in deep learning, particularly transfer learning, is gaining a preferred trend of research in medical image processing because of their admirable performance, even with small datasets. It inspires us to develop a novel deep learning-based leukemia detection system in which an efficient and lightweight MobileNetV2 is used in conjunction with ShuffleNet to boost discrimination ability and enhance the receptive field via convolution layer succession.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!